How big is the Global HER-2 Negative Breast Cancer Market?

The Global HER-2 Negative Breast Cancer Market size is expected to reach USD 15.03 billion in 2024 and grow at a CAGR of 9.17% to reach USD 23.32 billion by 2029. Read More

What is the current Global HER-2 Negative Breast Cancer Market size?

In 2024, the Global HER-2 Negative Breast Cancer Market size is expected to reach USD 15.03 billion. Read More

Who are the key players in Global HER-2 Negative Breast Cancer Market?

Eli Lilly and Company , AstraZeneca, GSK, Novartis AG and Pfizer are the major companies operating in the Global HER-2 Negative Breast Cancer Market. Read More

Which is the fastest growing region in Global HER-2 Negative Breast Cancer Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029). Read More

Which region has the biggest share in Global HER-2 Negative Breast Cancer Market?

In 2024, the North America accounts for the largest market share in Global HER-2 Negative Breast Cancer Market. Read More

What years does this Global HER-2 Negative Breast Cancer Market cover, and what was the market size in 2023?

In 2023, the Global HER-2 Negative Breast Cancer Market size was estimated at USD 13.77 billion. The report covers the Global HER-2 Negative Breast Cancer Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global HER-2 Negative Breast Cancer Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

HER-2 Negative Breast Cancer Market

HER-2 Negative Breast Cancer Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

HER-2 Negative Breast Cancer Market is segmented By Type of Treatment (Chemotherapy, Radiation Therapy, Hormonal Therapy, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market provides the value (in USD million) for the above-mentioned segments.

HER-2 Negative Breast Cancer Industry Overview

The primary focus among the companies is to develop combination therapies that shall overcome the resistance of existing drug therapies in the market thus boosting the targeted disease treatment. This is done via collaboration and partnerships among the market players. Some major companies in this segment include AstraZeneca, Bristol-Myers Squibb Company (Celgene Corporation), Eli Lilly and Company, GSK plc., Merck & Co., Inc., Novartis AG, and Pfizer Inc.